Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Complement Mediated Diseases”

36 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 36 results

Early research (Phase 1)Looking for participantsNCT05318534
What this trial is testing

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease

Who this might be right for
First in Man Study to Evaluate Initial Safety
Gliknik Inc. 70
Early research (Phase 1)Looking for participantsNCT06371417
What this trial is testing

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Who this might be right for
Antiphospholipid Syndrome (APS)Bullous Pemphigoid (BP)Behçet's Syndrome (BS)+3 more
Chugai Pharmaceutical 144
Early research (Phase 1)Not Yet RecruitingNCT06558656
What this trial is testing

Effect of Food of NTQ5082 in Healthy Subjects

Who this might be right for
Complement-mediated Hemolytic Diseases
Nanjing Chia-tai Tianqing Pharmaceutical 12
Early research (Phase 1)Not Yet RecruitingNCT06560593
What this trial is testing

Clinical Trial of NTQ5082 in Healthy Volunteers

Who this might be right for
Complement-mediated Hemolytic Diseases
Nanjing Chia-tai Tianqing Pharmaceutical 82
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07363265
What this trial is testing

Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease

Who this might be right for
Complement-mediated Renal Diseases
Longbio Pharma 46
Not applicableNot Yet RecruitingNCT07331259
What this trial is testing

CHART-C3G/CLNP023B12011

Who this might be right for
C3 GlomerulopathyComplement-mediated Kidney DiseaseProteinuria
Novartis Pharmaceuticals 83
Testing effectiveness (Phase 2)Looking for participantsNCT06853223
What this trial is testing

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

Who this might be right for
Primary Graft DysfunctionLung TransplantationAcute Lung Injury(ALI)+1 more
University of California, San Francisco 120
Early research (Phase 1)Study completedNCT06674915
What this trial is testing

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment

Who this might be right for
Complement Mediated Primary or Secondary Glomerular Diseases
Chengdu Suncadia Medicine Co., Ltd. 24
Early research (Phase 1)Study completedNCT03316521
What this trial is testing

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Who this might be right for
Complement Mediated Diseases
Amyndas Pharmaceuticals S.A. 50
Early research (Phase 1)Study completedNCT02502903
What this trial is testing

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders

Who this might be right for
Bullous Pemphigoid (BP)Cold Agglutinin Disease (CAD)Warm Autoimmune Hemolytic Anemia (WAIHA)+1 more
Bioverativ, a Sanofi company 122
Early research (Phase 1)Looking for participantsNCT07462780
What this trial is testing

A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria, PNHComplement-mediated Kidney Disease
Shenzhen Kangzhe Biotechnology Co., Ltd. 88
Early research (Phase 1)Study completedNCT05937581
What this trial is testing

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Who this might be right for
Complement-mediated Disorders
CSL Behring 62
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05517980
What this trial is testing

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

Who this might be right for
Glomerulonephritis
Kira Pharmacenticals (US), LLC. 52
Testing effectiveness (Phase 2)Study completedNCT05083364
What this trial is testing

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Who this might be right for
C3 GlomerulopathyIgA Nephropathy
Arrowhead Pharmaceuticals 62
Early research (Phase 1)Study completedNCT02983006
What this trial is testing

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
NYU Langone Health 12
Testing effectiveness (Phase 2)Study completedNCT03124368
What this trial is testing

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

Who this might be right for
C3 GlomerulonephritisDense Deposit DiseaseC3 Glomerulopathy+2 more
Alexion Pharmaceuticals, Inc. 6
Testing effectiveness (Phase 2)Looking for participantsNCT06989359
What this trial is testing

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Who this might be right for
IgANC3GComplement-mediated Kidney Disease+2 more
ADARx Pharmaceuticals, Inc. 45
Early research (Phase 1)Study completedNCT06797375
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants

Who this might be right for
Hematologic DiseasesAutoimmune Diseases
Rallybio 16
Not applicableWithdrawnNCT05304091
What this trial is testing

Characterization of Rhythmicity Profiles of Bradykinin-mediated Angioedema Attacks Using a Tracking Smartphone Application.

Who this might be right for
Bradykinin-mediated Angioedema
University Hospital, Lille
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06786338
What this trial is testing

SGB-9768 in Patients with Complement-mediated Kidney Diseases

Who this might be right for
IgA Nephropathy (IgAN)C3 GlomerulopathyIC-MPGN
Suzhou Sanegene Bio Inc. 38
Load More Results